NBTX announced a deal with Janssen Pharmaceutical.,to grant Janssen a license for the development of NBTXR3 and Nanobiotix will receive near term cash and operational support of $60m and is eligible for up to $1.8B.$强生(JNJ)$

$Nanobiotix(NBTX)$ $联拓生物(LIAN)$ 持有中国权益。